A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to test the safest and most effective dose of a new investigational drug, rebecsinib. Participants in this study will have either Secondary Acute Myeloid Leukemia (sAML) that has either returned (relapsed) or not responded to treatment (refractory) or have higher risk Myelofibrosis (MF). Participants will receive a study drug infusion on Day 1, Day 4, Day 8 and Day 11 of each 28-day cycle for a total of 6 cycles.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Zgoda pacjenta na uczestnictwo w badaniu i zrozumienie jego warunków
- •Rozpoznana powracająca lub oporna białaczka mieloidalna (sAML) lub wysokiego ryzyka miąższak kostny
- •Pacjent nie kwalifikuje się do przeszczepu szpiku kostnego
- •Wcześniejsze leczenie innymi terapiami (chemioterapia, azacytydyna, decytabina lub venetoklaks) bez skutku lub brak tolerancji
- •Prawidłowa funkcja nerek (czyszczenie kreatyniny > 60 mL/min)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
City of Hope Center
Duarte, United States
UC Davis Comprehensive Cancer Center
Sacramento, United States
UC San Diego Moores Cancer Center
San Diego, United States
Trial contact
Curis L Scribner, MD
Karla Mack
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/21/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.